Estragyn LA 5

Name: Estragyn LA 5

Estragyn LA 5 Overview

Estradiol is a prescription medication used to treat symptoms of menopause including hot flashes and vaginal dryness. It is also used to treat conditions in which a woman's ovaries do not produce enough estrogen naturally (hypoestrogenism).

Estradiol is a form of the hormone estrogen. It replaces estrogen that is not naturally produced by the ovaries.

This medication comes is available as a topical cream, a transdermal patch, a transdermal gel, a transdermal spray, a vaginal insert, and an oral tablet. It is usually taken once a day.

This medication is available in an injectable form to be given directly into a muscle (IM) by a healthcare professional.

Estradiol is also available in several combination products and hormonal contraceptives. This medication page only refers to the single-ingredient preparations.

Common side effects of estradiol include headache, breast pain, nausea, and bloating.

Estragyn LA 5 Precautions

Serious side effects have been reported with topical, oral, and injectable forms of estradiol including the following:

  • bulging eyes
  • yellowing of the skin or eyes
  • itching
  • loss of appetite
  • fever
  • joint pain
  • stomach tenderness, pain, or swelling
  • movements that are difficult to control
  • hives
  • rash or blisters on the skin
  • swelling, of the eyes, face, lips, tongue, throat, hands, feet, ankles, or lower legs
  • hoarseness
  • wheezing
  • difficulty breathing or swallowing

 

Do not take estradiol if you:

  • are allergic to estradiol or to any of its ingredients
  • have abnormal vaginal bleeding
  • have a known or suspected history of breast cancer
  • have a known or suspected estrogen-dependent cancer
  • have a history of blood clots
  • have liver disease
  • are pregnant or possibly pregnant

Estragyn LA 5 Food Interactions

Grapefruit and grapefruit juice may interact with estradiol and lead to potentially dangerous effects. Discuss the use of grapefruit products with your doctor.

Estragyn LA 5 Dosage

Take this medication exactly as prescribed by your doctor. Follow the directions on your prescription label carefully.

The dose your doctor recommends may be based on the following:

  • the condition being treated
  • other medical conditions you have
  • other medications you are taking
  • how you respond to this medication

 

Topical:

The recommended starting dose of estradiol transdermal patches for the treatment of menopause symptoms or hypoestrogenism is 0.025 mg daily applied to the skin once weekly.

The recommended starting dose of estradiol transdermal spray for the treatment of menopause symptoms is 1.53 mg daily applied to the skin of the forearm once daily.

The recommended starting dose of estradiol transdermal gel for the treatment of menopause symptoms is 0.25 g daily applied to the skin of the upper thigh once daily.

The recommended starting dose of estradiol vaginal cream for the treatment of menopause symptoms is 2 to 4 g daily applied to the skin of the upper thigh once daily.

The recommended starting dose of estradiol vaginal insert for the treatment of menopause symptoms is 0.05 or 0.10 mg daily inserted into the vagina every 3 months.

Oral:

The recommended dose range of estradiol oral tablets for the treatment of menopause symptoms is 1 to 2 mg daily by mouth.

Injectable:

The recommended dose range of estradiol cypionate intramuscular injection for the treatment of menopause symptoms is 1 to 5 mg injected every 3 to 4 weeks.

The recommended dose range of estradiol valerate intramuscular injection for the treatment of menopause symptoms is 10 to 20 mg injected every 4 weeks.

 

Estragyn LA 5 Overdose

If you take too much estradiol, call your healthcare provider or local Poison Control Center, or seek emergency medical attention right away.

If estradiol is administered by a healthcare provider in a medical setting, it is unlikely that an overdose will occur. However, if overdose is suspected, seek emergency medical attention.

Estragyn LA 5 FDA Warning

WARNING: ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER.CLOSE CLINICAL SURVEILLANCE OF ALL WOMEN TAKING ESTROGENS IS IMPORTANT. ADEQUATE DIAGNOSTIC MEASURES, INCLUDING ENDOMETRIAL SAMPLING WHEN INDICATED, SHOULD BE UNDERTAKEN TO RULE OUT MALIGNANCY IN ALL CASES OF UNDIAGNOSED PERSISTENT OR RECURRING ABNORMAL VAGINAL BLEEDING. THERE IS CURRENTLY NO EVIDENCE THAT THE USE OF “NATURAL” ESTROGENS RESULTS IN A DIFFERENT ENDOMETRIAL RISK PROFILE THAN SYNTHETIC ESTROGENS OF EQUIVALENT ESTROGEN DOSE.

CARDIOVASCULAR AND OTHER RISKS 

ESTROGENS WITH AND WITHOUT PROGESTINS SHOULD NOT BE USED FOR THE PREVENTION OF CARDIOVASCULAR DISEASE OR DEMENTIA.

THE WOMEN’S HEALTH INITIATIVE (WHI) STUDY REPORTED INCREASED RISKS OF MYOCARDIAL INFARCTION, STROKE, INVASIVE BREAST CANCER, PULMONARY EMBOLI, AND DEEP VEIN THROMBOSIS IN POSTMENOPAUSAL WOMEN (50 TO 79 YEARS OF AGE) DURING 5 YEARS OF TREATMENT WITH ORAL CONJUGATED ESTROGENS (CE 0.625 MG) COMBINED WITH MEDROXYPROGESTERONE ACETATE (MPA 2.5 MG) RELATIVE TO PLACEBO.

THE WOMEN’S HEALTH INITIATIVE MEMORY STUDY (WHIMS), A SUBSTUDY OF WHI, REPORTED INCREASED RISK OF DEVELOPING PROBABLE DEMENTIA IN POSTMENOPAUSAL WOMEN 65 YEARS OF AGE OR OLDER DURING 4 YEARS OF TREATMENT WITH ORAL CONJUGATED ESTROGENS PLUS MEDROXYPROGESTERONE ACETATE RELATIVE TO PLACEBO. IT IS UNKNOWN WHETHER THIS FINDING APPLIES TO YOUNGER POSTMENOPAUSAL WOMEN.

OTHER DOSES OF ORAL CONJUGATED ESTROGENS WITH MEDROXYPROGESTERONE ACETATE, AND OTHER COMBINATIONS AND DOSAGE FORMS OF ESTROGENS AND PROGESTINS WERE NOT STUDIED IN THE WHI CLINICAL TRIALS AND, IN THE ABSENCE OF COMPARABLE DATA, THESE RISKS SHOULD BE ASSUMED TO BE SIMILAR. BECAUSE OF THESE RISKS, ESTROGENS WITH OR WITHOUT PROGESTINS SHOULD BE PRESCRIBED AT THE LOWEST EFFECTIVE DOSES AND FOR THE SHORTEST DURATION CONSISTENT WITH TREATMENT GOALS AND RISKS FOR THE INDIVIDUAL WOMAN.

Share
(web3)